Jerusalem, Israel
Jerusalem, Israel

Time filter

Source Type

TEL AVIV, ISRAEL / ACCESSWIRE / February 28, 2017 / Elbit Imaging Ltd. (TASE: EMITF) (NASDAQ: EMITF) ("Elbit" or the "Company") announced today, in further to its announcement dated December 12, 2016, that it was informed by Gamida Cell Ltd. ("Gamida"), an indirect associate of the Company, that the first patient has been transplanted in Gamida's Phase 3 study of NiCord®, in development as a cure for patients with blood cancer (the "Trial".) The Trial is an international, randomized, controlled, open-label, multicenter, registration study. The trial is expected to enroll 120 patients, ages 16-60 that will be enrolled in medical centers in the U.S and Europe. The Trial will evaluate the safety and efficacy of transplanting NiCord® as compared to transplanting un-manipulated cord blood in patients with hematological malignancies (blood cancers). The primary end point is the time estimation to neutrophil engraftment. As of today, the development of NiCord remains at the clinical stage of development. Gamida develops cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Gamida's pipeline of products are in development to treat a wide range of conditions, including blood cancer, lymph nodes cancer and genetic hematological diseases such as sickle cell disease and thalassemia. The Company holds approximately 89.9% of the share capital of Elbit Medical Technologies Ltd. (TASE: EMTC) (85.6% on a fully diluted basis) which, in turn, holds approximately 25% of the share capital in Gamida (22.5% on a fully diluted basis). Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotel - operation and management of the Radisson hotel complex in Bucharest, Romania. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects. Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2015, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements. Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]


JERUSALEM, Feb. 28, 2017 /PRNewswire/ -- Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced today that the first patient has been transplanted in the Company's Phase 3 study of NiCord®, in development as a cure for...


Patent
Gamida Cell | Date: 2011-04-06

The present invention relates to an ex vivo method of expanding a population of cells ex-vivo, while at the same time, substantially inhibiting differentiation of the cells ex-vivo the method comprising: (a) culturing said cells under conditions which allow proliferation of said cells, and (b) ex-vivo providing said cells at the same time with added Nicotinamide, thereby ex-vivo expanding the population of cells while substantially inhibiting differentiation of the cells ex-vivo.


Patent
Gamida Cell | Date: 2015-12-15

Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses.


Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof.


A method of culturing mesenchymal stem cells (MSCs) is provided. The method comprising culturing a population of the MSCs in a medium comprising an aryl hydrocarbon receptor antagonist, thereby culturing MSCs.


Methods of ex-vivo culture of natural killer (NK) cells are provided and, more particularly, methods for enhancing propagation and/or functionality of NK cells by treating the cells with an aryl hydrocarbon antagonist in combination with cytokines driving NK cell proliferation. Also envisioned are compositions comprising cultured NK cells and therapeutic uses thereof.


Patent
Gamida Cell | Date: 2011-11-30

The present invention relates to a method of enhancing cell homing and engraftment potential, the method comprises ex-vivo or in vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient for enhancing cell homing and engraftment potential, the method is further characterized by at least one of the following:(i) wherein said amount of nicotinamide and said period of time are selected sufficient to down regulate CD26 expression by cells of said population of cells but not for stem and/or progenitor cell expansion;(ii) said population of cells does not include, mononuclear cells, early liver progenitor cells, committed progenitor cells, non-hematopoietic stem and progenitor cells, or embryonic stem and progenitor cells;(iii) said subjecting is in the absence of nutrients;(iv) said subjecting is in the absence of a cytokine;(v) said subjecting is in the absence of FLT-3 ligand;(vii) said subjecting is in the absence of stem cell factor (SCF);(vii) said subjecting is in the absence of granulocyte colony stimulating factor (GCSF);(viii) said subjecting is in the absence of an early acting cytokine; and(ix) said subjecting is in the absence of a late acting cytokine;and wherein said population of cells does not include a hematopoietic stem and/or progenitor cell population.


Patent
Gamida Cell | Date: 2012-02-13

Methods of culturing mesenchymal stem cells are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide and fibroblast growth factor 4 (FGF4). Populations of mesenchymal stem cells generated using the methods described herein and uses thereof are also provided.


Mesenchymal stem cell conditioned medium and methods for preparing the conditioned medium are provided. The methods comprise culturing MSCs in a medium comprising nicotinamide or nicotinamide and fibroblast growth factor 4 (FGF4) and collecting the conditioned medium. Compositions comprising the mesenchymal stem cell conditioned medium and uses thereof are also provided.

Loading Gamida Cell collaborators
Loading Gamida Cell collaborators